Oncology Institute (STLN) Stock Price, News & Analysis

Company Overview

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs. It also participates in clinical research and may offer access to clinical trials and emerging cancer therapies through its physician and provider network.

The Oncology Institute primarily serves patients in the United States through oncology clinics and affiliated providers, with a focus on making specialized cancer care more accessible outside traditional hospital systems. The company works with health plans and other healthcare organizations under value-based arrangements intended to emphasize care coordination, outcomes and the overall patient experience.

Key Stats

• Today's Range: $6.19 to $6.81
• 50-Day Range: $5.91 to $7.05
• 52-Week Range: $2.32 to $7.13
• Volume: 1.86 million shs
• Average Volume: 1.15 million shs
• Market Capitalization: $621.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Moderate Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oncology Institute has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncology Institute has a consensus price target of $9.00, representing about 43.1% upside from its current price of $6.29.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncology Institute are expected to grow in the coming year, from ($0.21) to ($0.05) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.92% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 5.62.

Change versus previous month

Short interest in Oncology Institute has recently decreased by 3.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Oncology Institute this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for STLN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold 2,379.02% more of their company's stock than they have bought. Specifically, they have bought $78,480.00 in company stock and sold $1,945,533.00 in company stock.

Percentage Held by Insiders

4.40% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

36.86% of the stock of Oncology Institute is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:STLN
• Previous Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: www.starlingoncology.com
• Phone: (562) 735-3226
• Fax: N/A
• Employees: 641
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +43.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$60.61 million
• Net Margins: -6.18%
• Pretax Margin: -6.18%
• Return on Equity: N/A
• Return on Assets: -21.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.36
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $502.73 million
• Price / Sales: 1.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.16) per share
• Price / Book: -39.31

Miscellaneous

• Outstanding Shares: 98,840,000
• Free Float: 94,490,000
• Market Cap: $621.70 million
• Optionable: Optionable
• Beta: 0.39